



Benjamin Fuhrmann

Associate

T 416.367.7864
F 416.367.6749
Toronto
BFuhrmann@blg.com
[LinkedIn](#)

[Corporate Commercial](#)
[Products Law](#)
[Health Care & Life Sciences](#)
[Corporate Governance](#)
[MedTech](#)
[Health Regulatory](#)
[Charities & Not-For-Profit](#)
[International Business & Human Rights](#)
[Technology](#)

Ben practices corporate, commercial, and regulatory law with a focus on the life sciences, technology, manufacturing, retail, and healthcare sectors.

Ben advises on a wide range of matters including corporate governance, commercial agreements, mergers & acquisitions, corporate reorganizations, and product regulatory compliance and enforcement.

Within his corporate and commercial practice, Ben routinely supports organizations by drafting and negotiating a broad spectrum of agreements, including those related to supply of goods and services, research collaborations, and intellectual property licensing. He assists companies in corporate restructurings, mergers & acquisitions, and developing procedures for supply chain due diligence. He frequently advises charities and not-for profits, including hospitals, foundations, and community health centres, on governance best practices and on navigating sensitive matters that may involve reputational risk.

In his product regulatory practice, Ben provides strategic guidance to companies entering or operating in the Canadian market, including on product compliance, labelling, warnings, advertising, recalls, and responding to enforcement action from some of Canada's key product regulators, including Health Canada and Innovation, Science, and Economic Development Canada. Ben has particular experience in assisting both domestic and international companies that manufacture, import, and/or sell medical devices, pharmaceuticals, foods, and natural health products. He also has significant experience advising on sale of good and consumer protection

legislation across the country, assisting manufacturers and online retailers develop compliant contracts of sale, terms of service, and warranty documentation.

Prior to attending law school, Ben completed a Master of Science degree in Immunology. His research focused on developing new immunosuppression medication for kidney transplant patients.

Ben is a member of Medtech Canada and a co-author of LexisNexis' Canadian Food and Drug Legislation & Commentary, 2025 Edition.

Experience

- Counsel to Guardian Capital Group Limited in its \$1.67 billion go-private transaction with Desjardins Global Asset Management Inc.

Insights & Events

- Author, "Tracking progress in modern slavery reporting: Insights from Public Safety Canada's 2025 annual report", BLG Article, October 2025
- Author, "A new era: Health Canada signals modernization in policy and regulatory reform", BLG Article, September 2025
- Author, "One template, three jurisdictions: New guidance on modern slavery reporting in Canada, Australia, and the UK", BLG Article, September 2025
- Author, "Health Canada's Product Safety Pledge: A model product safety framework for Consumer Products and Cosmetics", BLG Article, September 2025
- Author, "Mandatory front-of-package labelling compliance by 2026 — Are you prepared?", BLG Article, May 2025
- Author, "Canada's mandatory Federal Plastics Registry reporting: What you need to know", BLG Article, April 2025
- Author, "Health Canada's evolving regulatory framework for machine learning-enabled medical devices", BLG Article, February 2025
- Author, "Better guidance equals better reporting: Navigating the Supply Chains Act for year 2 reporting", BLG Article, November 2024
- Author, "Introduction to the Pharmacare Act: A New Era for Pharmacare in Canada", BLG Article, October 2024
- Author, "Modern slavery reporting: Key lessons from Public Safety Canada's 2024 annual report to Parliament", BLG Article, October 2024
- Author, "Regulatory framework of laboratory developed tests: Canada vs U.S.", BLG Article, July 2024
- Co-Author, "Q&A: defamation claims in Canada," Lexology, October 2023.
- Author, "Health Canada releases draft pre-market guidance for machine learning medical devices", BLG Article, September 2023
- Author, "The Canadian legal landscape on AI enabled medical devices", BLG Article, June 2023
- Author, "Hansman v. Neufeld – SCC decision confirms that certain “counter-speech” is deserving of protection", BLG Article, May 2023
- Author, "Health Canada releases guiding principles on artificial intelligence and machine learning for medical devices", BLG Article, November 2021
- Author, "Health Canada regulatory spotlight on medical device post-market surveillance", BLG Article, November 2021

- Author, "ON court: Class actions appropriate procedure for negligent misrepresentation claim", BLG Article, July 2020

Beyond Our Walls

Professional involvement

- Member, Law Society of Ontario
- Member, Ontario Bar Association

Bar Admission & Education

- Ontario, 2022
- JD, Western University, 2021
- MSc. Immunology, Western University, 2018
- B.Sc. (Hons.) Microbiology & Immunology, Western University, 2016

BLG | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 800 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

[blg.com](https://www.blg.com)

© 2026 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.